ONC-392,Pembrolizumab
biontech,Merck
['lcsm,(-blcsm)']
 a new anti-ctla4 in the block: onc-392/bnt316. decreasing toxicity by leaving ctla-4 receptor available in the tme while keeping antitumor activity. 30% orr in previously io-treated population. #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm